Cited by 14Cancer Immunotherapy and Biomarkersinterferon and immune responsesImmunotherapy and Immune Responses

Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation

Open access
Alshebremi, Mohammad, Tomchuck, Suzanne L, Myers, Jay T, Kingsley, Daniel T, Eid, Saada, Abiff, Muta, Bonner, Melissa, Saab, Shahrazad T +2 more·2023·Journal for ImmunoTherapy of Cancer

Abstract

Background: Despite its potential utility in delivering direct tumor killing and in situ whole-cell tumor vaccination, tumor cryoablation produces highly variable and unpredictable clinical response, limiting its clinical utility. The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood. Methods: The aim of this study was to identify and explore a mechanism of action by which cryoablation enhances the therapeutic efficacy in metastatic tumor models. We used the subcutaneous mouse model of the rhabdomyosarcoma (RMS) cell lines RMS 76-9 STINGwt or RMS 76-9 STING-/-, along with other murine tumor models, in C57BL/6 or STING-/- (TMEM173-/- ) mice to evaluate local tumor changes, lung metastasis, abscopal effect on distant tumors, and immune cell dynamics in the tumor microenvironment (TME). Results: The results show that cryoablation efficacy is dependent on both adaptive immunity and the STING signaling pathway. Contrary to current literature dictating an essential role of host-derived STING activation as a driver of antitumor immunity in vivo, we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME. This reliance extends beyond cryoablation to include intratumoral STING agonist therapy. Additionally, surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components. Conclusions: Tumor cell-intrinsic STING pathway is a critical component underlying the effectiveness of cryoablation and suggests that expression of STING-related signaling components may serve as a potential therapy response biomarker. Our data also highlight an urgent need to further characterize tumor cell-intrinsic STING pathways and the associated downstream inflammatory response evoked by cryoablation and other STING-dependent therapy approaches.

AI snapshot

Written from the paper’s full text.

TL;DR

Cryoablation efficacy in murine sarcoma and pancreatic tumor models depends on adaptive immunity and, unexpectedly, on functional STING signaling within the live residual tumor cells rather than host STING. Tumor cell-intrinsic STING also drives systemic abscopal responses and contributes to intratumoral STING agonist therapy, with clinical sarcoma data showing variable STING pathway expression.

Key findings

  • Cryoablation required adaptive immunity: in nude mice the effect was greatly reduced and all mice succumbed after the last measurement on day 21; CD4+ T-cell depletion partially abrogated regression, while CD8+ T-cell depletion resulted in tumor growth not significantly different from untreated tumors.
  • Tumor cell-intrinsic STING was critical: cryoablation of RMS 76-9STING−/− tumors was completely ineffective in C57BL/6 mice despite intact host STING, with significantly increased lung metastases; in STING−/− mice, cryoablation of RMS 76-9STINGwt still significantly inhibited tumor growth and lung metastases, whereas STING−/− tumors did not benefit. Similar results were seen with M3-9-M and KPC1242 models.
  • The abscopal effect depended on the primary tumor’s STING: cryoablation of RMS 76-9STINGwt primary tumors significantly reduced untreated contralateral RMS 76-9STINGwt secondary tumors in both C57BL/6 and STING−/− mice, but this effect was lost when the primary tumor was STING−/−.
  • Intratumoral DMXAA (250 µg) efficacy was also tumor-intrinsic STING-dependent: absence of STING in tumor cells or host alone partially suppressed tumor growth, while absence in both completely abolished in vivo antitumor efficacy. Clinical surveys found wide variation in STING pathway components across 2142 PeCan samples and an RMS tissue microarray from 104 patients, with lower Tmem173 and Tbk1 transcript expression in metastatic/relapsed RMS versus primary tumors.

Methods

  • Subcutaneous mouse tumor models used RMS 76-9STINGwt or CRISPR-generated RMS 76-9STING−/− cells, plus M3-9-M and KPC1242 counterparts, in male C57BL/6, nude, or STING−/− mice; only male mice were used because RMS 76-9 originated from male mice and female mice reject H-Y-dependent tumors.
  • Primary tumors were cryoablated at ~100 mm³ with three cycles of 1 min freeze and 3 min thaw; outcomes included local tumor growth, lung metastasis, dual-tumor abscopal effect, TME immune profiling by flow cytometry/t-SNE, qPCR, ELISA, chemokine/cytokine arrays, western blot, immunohistochemistry, and confocal imaging.
  • In vitro assays included BMDC and BMDM co-culture with cryoablated tumor cells, DMXAA treatment, proliferation/cell death analysis, and STING pathway validation; statistics used GraphPad Prism V8 with mean ± SEM, two-tailed t-tests, one-way or two-way ANOVA with Bonferroni’s multiple comparisons.

Limitations

  • Stated: the study used a single cryoablation intervention to standardize parameters, so whether different timing, duration, or frequency would enhance antitumor immunity remains undetermined; the abscopal tumors remained sizeable and many progressed, suggesting combination therapy such as immune checkpoint blockade may be needed; whether the effect converges on IFN-β, chemokines, or other undiscovered effectors remains to be determined; direct effects of tumor-intrinsic STING on metastatic potential versus immunogenicity require further investigation.
  • Evident from the text: only male mice were used, limiting sex-related generalizability; the clinical STING expression analyses are correlative surveys of databases and tissue microarrays rather than causal clinical validation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/jitc-2022-006608

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

32 of 48 cited sources checked · 9 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    CD8+IFN-γ+ T cells are an effector population shown to be a target of downstream STING signaling involving the IFN-β-CXCL9/10 axis.

    “an effector population shown to be a target of downstream STING signaling involving the IFN-β-CXCL9/10 axis.54–58”
    Quote in the paperSubstantial claim5 of 5 sources checked
    • cites [54] source

      The sections “Regulation of the STING pathway in APCs and its role in cancer” and “Type I IFNs in the generation of antitumor immune responses” link STING activation to IFN-β production and antitumor CD8+ T-cell responses. The latter section also associates CXCL9 and CXCL10 with T-cell recruitment, but our copy does not establish the stated IFN-β–CXCL9/10 signaling axis or identify CD8+IFN-γ+ T cells specifically as its target. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [55] source

      The Results section (page unavailable) shows that CXCL9 and CXCL10 recruit human CD8+ effector T cells in migration assays. It does not identify those cells as IFN-γ+ or establish that their recruitment is downstream of STING signaling through IFN-β. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [56] Vonderhaar, 2021, STING activated tumor-intrinsic type I interferon signaling promotes Cxcr3 dependent antitumor immunity in Pancreatic cancer, Cell Mol Gastroenterol Hepatol source

      The Results section reports that STING agonist increased IFN-β expression and the frequency of CXCR3+CD8+ T cells in pancreatic tumor models. The Discussion links STING activation, type I interferon signaling, and CXCL9/CXCL10 to effector T-cell infiltration. Our copy does not establish that the affected CD8+ cells were specifically IFN-γ+. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [57] source

      The Results section reports reduced T-cell infiltration in STING-deficient tumors and links effector T-cell migration to CXCL9/10-producing dendritic cells; it also describes STING-dependent IFN-β and CXCL9/10 production. The paper supports this pathway for effector CD8+ T-cell recruitment, but does not establish that the recruited CD8+ cells are specifically IFN-γ-positive. Its Discussion separately identifies IFN-γ-producing CD4+ Th1 cells. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [58] Reschke R , Olson DJ . Leveraging STING, Batf3 Dendritic cells, Cxcr3 ligands, and other components related to innate immunity to induce A "hot. Cancers (Basel 2022;14(10. source

      Section 3.1 (page unavailable) states that STING-induced CXCL9/10 expression depends on type I interferons, including IFN-β. Section 3 (page unavailable) says CXCL9/10 promote T-cell migration and are associated with CD8+ effector T cells. The paper does not specifically identify CD8+IFN-γ+ T cells as a demonstrated target of that signaling axis. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
  • Premisecitation

    Clinical outcomes of tumor cryoablation-both obtaining local control and achieving an abscopal effect-are highly unpredictable with variable magnitudes of response and frequent failure of local recurrence.

    “Despite these theoretical benefits, clinical outcomes of tumor cryoablation—both obtaining local control and achieving an abscopal effects—are highly unpredictable with variable magnitudes of response and frequent failure of local recurrence.”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [76] Aarts, 2019, Cryoablation and Immunotherapy: an overview of evidence on its synergy, Insights Imaging source

      The Abstract and Introduction say the abscopal effect is rarely observed, supporting that part of the claim. But the Conclusion says cryoablation has proven successful for local control in various cancers; it does not describe local control as highly unpredictable or report frequent local failure. The cited passages also do not establish variable magnitudes of clinical response. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [77] Yakkala, 2019, Cryoablation and Immunotherapy: an enthralling synergy to confront the tumors, Front Immunol source

      The ‘Critical Aspects’ section (page unavailable) says some patients experience local tumor progression after cryoablation and that factors governing its effects remain ill-defined. The ‘Immunology of Cryoablation’ section (page unavailable) describes variable immune responses and limited abscopal regression. These passages support uncertainty in outcomes, but the source says only a fraction of patients have local progression, not that local failure is frequent. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [78] Baust, 2019, Cryoablation: physical and molecular basis with putative immunological consequences, Int J Hyperthermia source

      The Cryo-immunological Responses section (page unavailable) says distant-tumor effects are not always observed, are transient, and vary in extent; the Introduction says freezing does not damage a targeted tumor uniformly. These passages support variable responses, but they do not establish that clinical local control is highly unpredictable or that local recurrence frequently occurs. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • Premisecitation

    Gain-of-function STING-N153S mutation resulted in T cell deficiency.

    “and gain-of-function STING-N153S mutation resulted in T cell deficiency.85”
    Quote in the paperNot a substantial claim1 of 1 sources checked
  • Premisecitation

    STING activity induces T cell apoptosis.

    “as recent evidence demonstrated that STING activity induces T cell apoptosis,85–87”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [85] source
    • cites [86] Gulen, 2017, Signalling strength determines Proapoptotic functions of STING, Nat Commun source
    • cites [87] source

      The Results and Discussion section (“STING activation triggers T cell death”; page not provided) reports STING-dependent T-cell death in vitro and evidence implicating an apoptotic pathway. But it also suggests necroptosis can contribute and reports no T-cell death in its short-term in vivo experiment, so the unqualified claim that STING activity induces T-cell apoptosis overstates the finding. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
  • Findingown data

    Cryoablation of RMS 76-9STING-/- tumors in C57BL/6 mice was rendered completely ineffective, despite functionally intact STING signaling in the host.

    “cryoablation of RMS 76-9STING-/- tumors in C57BL/6 mice was rendered completely ineffective, despite the presence of functionally intact STING signaling in the host (figure 4A).”
    Quote in the paperSubstantial claim
  • Classified as probably not a substantial claim. 24
  • May combine two claims. 27
  • The quote only partly states this claim. 1
  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Clinical response to cryoablation is highly variable and lacks a reliable biomarker predicting a beneficial therapeutic outcome.

    “Despite these theoretical advantages, clinical response to cryoablation is highly variable and suffers from the absence of a reliable biomarker that predicts a beneficial therapeutic outcome of this approach.15”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [15] Baust, 2014, Mechanisms of Cryoablation: clinical consequences on malignant tumors, Cryobiology source

      The Introduction describes inherent variability in cryoablative applications, and the Summary notes persistent disease after freezing. These passages partly support variable outcomes, but they do not establish that clinical response is highly variable or state that a reliable predictive biomarker is absent. Page numbers are unavailable in our copy. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
  • Classified as probably not a substantial claim.

    Premisecitation

    Recent evidence suggests that tumor cell-intrinsic STING is critical to the production of type I IFNs and promotion of CD8+ T cell activation via enhancing the function of APCs.

    “As recent evidence suggests that tumor cell-intrinsic STING is critical to the production of type I IFNs and promotion of CD8+ T cell activation via enhancing the function of APCs,33”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [33] source

      The Results sections on type I IFN activation and epitope-specific T cell activation report that STING-deficient dMLH1 tumor cells lose type I IFN signaling and are less able to support dendritic-cell-mediated CD8+ T cell priming. The evidence is specific to MLH1-deficient or dMMR tumor models; the claim does not retain that condition and could be read as applying to tumor cells generally. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
  • Probably not a substantial claim: may not pass S1 (asserted).

    Premisecitation

    It has been proposed that tumor cell-intrinsic STING enhances tumor immunogenicity by increasing immune cell activation and triggering tumor cell regression.

    “it has been proposed that tumor cell-intrinsic STING enhances tumor immunogenicity by increasing immune cell activation and triggering tumor cell regression.47–49”
    Quote in the paperNot a substantial claim3 of 3 sources checked
    • cites [47] source

      The Results section ('Intratumoral STING pathway activation is required for olaparib-induced T cell recruitment and anti-tumor efficacy'; page not supplied) links tumor-cell STING activation to CD8+ T-cell recruitment and activation, and reports reduced tumor burden with olaparib when tumor-cell STING is intact. It does not establish tumor regression, and its findings concern PARP-inhibitor-treated, BRCA-deficient breast cancer models rather than tumor-cell STING activation generally. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [48] source
    • cites [49] Yang, 2021, Zbp1-MLKL Necroptotic signaling potentiates radiation-induced antitumor immunity via Intratumoral STING pathway activation, Sci Adv source

      The Results section reports that tumors lacking STING had poorer control after radiation and fewer activated, tumor-specific CD8+ T cells, supporting a role for tumor cell–intrinsic STING in antitumor immunity. The evidence is specific to radiation-treated tumors; it reports tumor control rather than explicitly showing that STING triggers tumor regression more generally. No page number is available in our copy. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
  • Classified as probably not a substantial claim.

    Premisecitation

    Different tumor models have shown variability in their responses to STING signaling.

    “As different tumor models have shown variability in their responses to STING signaling,66”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [66] Kim, 2023, Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity, Cancer Immunol Immunother source
  • May combine two claims.

    Findingown data

    In post-cryoablated RMS 76-9STINGwt TME compared with RMS 76-9STING-/- TME in wild-type mice, there was a significant increase in total CD4+ T cells expressing IFN-γ and GZMB, NK cells, GZMB expression in CD8+ T cells, and Foxp3+ CD4+ cells.

    “we observed a significant increase in the total CD4+ T cells expressing IFN-γ (figure 4H) and granzyme B (GZMB; figure 4J),60–65 NK cells (figure 4N), and the amount of GZMB expression in CD8+ T cells (figure 4L) in the post-cryoablated RMS 76-9STINGwt TME as compared with RMS 76-9STING-/- TME in wild-type mice, as was Foxp3+ CD4+ cells (figure 4M).”
    Quote in the paperSubstantial claim6 of 6 sources checked
    • cites [60] Knelson, 2022, Activation of tumor-cell STING primes NK-cell therapy, Cancer Immunol Res source

      The Results section on dynamic scRNA-seq of MPM explants identifies granzyme-positive T cells and NK cells, but it does not report the claimed increases after cryoablation. Searches for RMS 76-9, cryoablation, and the STING-wild-type versus STING-knockout comparison found no passage addressing that experiment in our copy. (LLM, conf=0.75)

      Experimental — accuracy not yet measured
    • cites [61] Berger, 2022, STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models, Proc Natl Acad Sci U S A source

      The Results section, “STING Activation in Intracranial GBM Models Drives Innate Immune Cell Infiltration” (page unavailable), reports increased NK-cell infiltration after STING-agonist treatment. It studies glioblastoma models, not cryoablated RMS 76-9 tumors, and does not support the stated RMS comparison or the specific IFN-γ, granzyme B, and Foxp3+ CD4+ cell increases. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites [62] Śledzińska, 2020, Regulatory T cells restrain Interleukin-2- and Blimp-1-dependent acquisition of cytotoxic function by Cd4+ T cells, Immunity source
    • cites [63] source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [64] source

      Split into 2 atoms — 1 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [65] Takeuchi, 2017, Cd4 CTL, a cytotoxic subset of Cd4(+) T cells, their differentiation and function, Front Immunol source

      The Introduction says cytotoxic CD4+ T cells can contain granzyme B, and the Differentiation of CD4 CTL section discusses IFN-γ production. Neither section reports the cited increase after cryoablation, the RMS 76-9 STING comparison, or the NK, CD8+, and Foxp3+ findings; those are presented in the citing sentence as its authors’ own observations. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • Classified as probably not a substantial claim.

    Premisecitation

    Previous studies have suggested that the tumor cell-intrinsic STING pathway may be essential in triggering antitumor immunity in other contexts.

    “Previous studies have suggested that the tumor cell-intrinsic STING pathway may be essential in triggering antitumor immunity in other contexts.47–49”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [47] source
    • cites [48] source
    • cites [49] Yang, 2021, Zbp1-MLKL Necroptotic signaling potentiates radiation-induced antitumor immunity via Intratumoral STING pathway activation, Sci Adv source
  • Classified as probably not a substantial claim.

    Premisecitation

    The current dogma dictates that the host-derived STING pathway is the converging critical responder.

    “a finding that is in sharp contrast to the current dogma which dictates that host-derived STING pathway is the converging critical responder.79–81”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [79] Ni, 2022, T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by Upregulating Foxp3 transcription in Cervical cancer, J Immunother Cancer source

      The Introduction (page unavailable) says STING signaling in immune cells is needed for type I IFN-dependent T-cell priming and NK-cell cytotoxicity, supporting an important role for host-cell STING in antitumor immunity. It does not establish the broader claim that host-derived STING is the converging critical responder; the Discussion (page unavailable) also describes a distinct role for T-cell-intrinsic STING. (LLM, conf=0.78)

      Experimental — accuracy not yet measured
    • cites [80] Luo, 2022, Transcription-independent regulation of STING activation and innate immune responses by Irf8 in monocytes, Nat Commun source

      The Introduction describes STING as critical to innate immune responses and notes that the cGAS–STING pathway is involved in anti-tumor immunity. The Discussion also links STING to cancer prognosis. Neither section establishes the more specific claim that host-derived STING is the converging critical responder. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [81] Kabashima, 2022, cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in Pancreatic cancer, Sci Rep source

      The Introduction (page unavailable) describes cGAS-STING as a crucial regulator of tumor immunity, supporting the pathway’s general importance. It does not identify host-derived STING as the converging critical responder. The Discussion (page unavailable) reports lower recruitment of CD8+ T cells toward cancer cells in stromal-STING-dominant cases than in cases with cancer-cell cGAS-STING expression, while cautioning that there were too few stromal-dominant cases for firm conclusions. (LLM, conf=0.78)

      Experimental — accuracy not yet measured
  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need, with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.

    “of which recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need,88–90 with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.91–95”
    Quote in the paperNot a substantial claim2 of 8 sources checked
    • cites [88] source
    • cites [89] source
    • cites [90] source
    • cites [91] source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [92] source
    • cites [93] source

      Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [94] source
    • cites [95] Raney, 1988, Disease patterns and survival rate in children with metastatic soft-tissue sarcoma, A Report from the Intergroup Rhabdomyosarcoma Study (IRS)-I Cancer source
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components.

    “Additionally, surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Findingown data

    Cryoablation effectively reduced the size of established RMS 76-9 tumor mass and suppressed local recurrence over the following 2 weeks.

    “Cryoablation effectively reduced the size of the established tumor mass while suppressing the rate of local recurrence over the following 2 weeks (figure 1A).”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    There were clear differences in the TME expression profiles for each treatment group as shown by the number of events per cluster in density plots.

    “There were clear differences in the TME expression profiles for each treatment group as shown by the number of events per cluster in each of the density plots (figure 4E).”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Findingown data

    The effect of cryoablation was greatly reduced in nude mice, which all succumbed to disease days after the last tumor measurement on day 21.

    “the effect of cryoablation was greatly reduced in nude mice which all succumb to disease days after the last tumor measurement on day 21”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Cryoablation of M3-9-MSTINGwt and KPC1242STINGwt resulted in significantly reduced tumor burden in C57BL/6 mice, while the same intervention was ineffectual against M3-9-MSTING-/- and KPC1242STING-/- tumors, even in C57BL/6 mice with intact host STING signaling pathways.

    “Similar to RMS 76-9, cryoablation of M3-9-MSTINGwt and KPC1242STINGwt resulted in significantly reduced tumor burden in C57BL/6 mice mice, while the same intervention was ineffectual against M3-9-MSTING-/- and KPC1242STING-/- tumors, even in C57BL/6 mice with intact host STING signaling pathways (figure 6).”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Caspase-3 staining data suggest a slightly higher basal level of Caspase-3+ tumor cells among RMS 76-9STING-/- tumors.

    “our Caspase-3 staining data suggest that there appears to be a slightly higher basal level of Caspase-3+ tumor cells among RMS 76-9STING-/- tumors (online supplemental figure S9E)”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Findingown data

    Treatment with DMXAA impaired RMS 76-9STINGwt growth in a dose-dependent manner, while RMS 76-9STING-/- was not affected until a high DMXAA dose range.

    “Treatment with DMXAA impaired RMS 76-9STINGwt growth in a dose-dependent manner, while 76-9STING-/- was not affected until a high DMXAA dose range (online supplemental figure S8B).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Cryoablation of RMS 76-9STINGwt was efficacious in suppressing primary tumor growth and preventing lung metastasis regardless of whether the tumor-bearing hosts express functional STING in all tissue compartments.

    “Surprisingly, cryoablation of RMS 76-9STINGwt was efficacious in suppressing primary tumor growth, as well as preventing lung metastasis regardless of whether or not the tumor-bearing hosts express functional STING in all tissue compartments.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    The tumor reduction efficacy of cryoablation in the primary tumor was completely lost in the context of RMS 76-9STING-/- tumor, while RMS 76-9STINGwt primary tumor exhibited a robust response.

    “The tumor reduction efficacy of cryoablation in the primary tumor was completely lost in the context of RMS 76-9STING-/- tumor (figure 8B, black), while RMS 76-9STINGwt primary tumor exhibited a robust response (figure 8B, yellow)”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingcitation

    Cryoablation enhanced the infiltration of total CD45+ cells and functional CD8+ T cells and increased the expression of co-stimulatory molecules on DCs.

    “Cryoablation enhanced the infiltration of total CD45+ cells and functional CD8+ T cells82 and increased the expression of co-stimulatory molecules on DCs.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [82] source
  • May combine two claims.

    Findingown data

    Neither tumor-bearing C57BL/6 nor STING-/- mice benefited from cryoablation when treating RMS 76-9STING-/- tumor, and experienced rampant lung metastasis.

    “In sharp contrast to RMS 76-9STINGwt tumor, however, neither tumor-bearing C57BL/6 nor STING-/- mice benefited from cryoablation when treating RMS 76-9STING-/- tumor, and experienced rampant lung metastasis.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Live RMS 76-9 maintains a functional STING signaling pathway and serves as a major source of IFN-β after STING activation either by co-culturing with cryoablated tumor or DMXAA.

    “In addition to being a potential source of CDN/cGAMP, live RMS 76-9 maintains a functional STING signaling pathway and serves as a major source of IFN-β after STING activation either by co-culturing with cryoablated tumor or DMXAA.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Chemokine and cytokine protein production was not significantly changed before and after cryoablation in STING-/- tumor TME, even though the host stroma contains a functional STING signaling pathway.

    “chemokine and cytokine protein production was not significantly changed before and after cryoablation in STING-/- tumor TME, even though the host stroma contains a functional STING signaling pathway (figure 7B–D).”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Cryoablation failed to control primary tumor growth in immune-deficient mice, resulting from rapid local recurrence and metastasis following cryoablation.

    “as cryoablation failed to control primary tumor growth in immune-deficient mice resulting from rapid local recurrence and metastasis following cryoablation.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Downstream signaling molecule activation in the tumor-intrinsic STING signaling pathway requires time (up to 4 hours) and the effect can be transient.

    “Our investigation into tumor-intrinsic STING signaling pathway kinetics suggests that downstream signaling molecule activation requires time (up to 4 hours) and the effect can be transient.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    Our survey of available pediatric tumor databases revealed heterogeneous expression patterns among pediatric cancers.

    “Our survey of available pediatric tumor databases revealed a heterogeneous expression patterns among pediatric cancers”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Findingown data

    The abscopal tumor remained sizeable and many progressed over time in the co-implantation tumor model.

    “Despite the overall improvement in the abscopal efficacy in our co-implantation tumor model, the abscopal tumor remained sizeable and many progressed over time”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Findingown data

    Little change in the cytokine and chemokine arrays were observed in the RMS STING-/- TME following cryoablation, despite the host being fully capable of responding to STING activation.

    “In contrast, little change in the cytokine and chemokine arrays were observed in the RMS STING-/- TME following cryoablation, despite the host being fully capable of responding to STING activation (figure 7).”
    Quote in the paperSubstantial claim
  • Classified as probably not a substantial claim.

    Premisecitation

    Prior reports have described an essential role for host STING pathway in cancer therapy.

    “As prior reports have described an essential role for host STING pathway in cancer therapy,17 35 36 54”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites 17 35 36 54

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim.

    Study design and conductown data

    RMS 76-9STING-/- knockout efficiency was confirmed by western blot.

    “gene knockout efficiency was confirmed by western blot.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    Flow cytometry analyses of TME immune composition were performed with freshly isolated single cell suspensions without freeze-thaw manipulations.

    “All flow cytometry analyses of the TME immune composition were performed with freshly isolated single cell suspensions obtained on the same day of tumor harvesting without freeze-thaw manipulations.”
    Quote in the paperNot a substantial claim
  • May combine two claims.

    Study design and conductown data

    Tmem173 expression was ablated via CRISPR-Cas9 in RMS 76-9STING-/- cells, confirmed by western blot and qPCR.

    “then ablated Tmem173 expression via CRISPR-Cas9 genome editing (RMS 76-9STING-/-), which was confirmed by both western blot (online supplemental figure S4A) and qPCR (online supplemental figure S4B).”
    Quote in the paperSubstantial claim
  • Classified as probably not a substantial claim.

    Premisecitation

    dsDNA derived from tumor cells as a result of cytotoxic agents or stress can trigger STING pathway activation in nearby host APCs, resulting in the release of IFN-β, chemokines CXCL9/10, and enhanced cross-presentation of tumor antigens to CD8+ T cells.

    “Previous studies have shown that dsDNA derived from tumor cells as a result of cytotoxic agents or stress can trigger STING pathway activation in nearby host APCs, resulting in the release of IFN-β, chemokines CXCL9/10, and enhanced cross-presentation of tumor antigens to CD8+ T cells.17 35 36 54–58”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites 17 35 36 54–58

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims. The quote only partly states this claim.

    Interpretationown data

    Host STING signaling activation and associated type I IFN production provide partial local tumor control following cryoablation but cannot fully account for the complete in vivo therapeutic effects observed in wild-type mice.

    “our data indicate that the host STING pathway plays a partial role in regulating RMS 76-9 tumor growth, as the antitumor immune response of cryoablation was impaired but not completely abrogated in STING-/- mice (figure 3E).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: STING-/- mice lack functional host STING signaling.
  • May combine two claims.

    Interpretationown data

    Cryoablation may activate antitumor immune responses by supporting DC maturation and recruitment of hematopoietic cells to the TME.

    “These results suggest that cryoablation may activate antitumor immune responses by supporting DC maturation and recruitment of hematopoietic cells to the TME.”
    Quote in the paperSubstantial claim
  • Classified as probably not a substantial claim.

    Study design and conductreasoning

    Only male mice were used to eliminate confounding issues related to H-Y dependent tumor rejection.

    “To eliminate confounding issues related to H-Y dependent tumor rejection, only male mice were used in this study.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: RMS 76-9 originated from male mice, and female mice spontaneously reject inoculated tumor growth at a high frequency.
  • May combine two claims.

    Interpretationown data

    The presence of an intact tumor cell-derived STING signaling is critical for in vivo tumor rejection not only in the setting of cryoablation but also in the setting of therapies involving direct STING agonist administration.

    “These data suggest that the presence of an intact tumor cell-derived STING signaling is critical for in vivo tumor rejection not only in the setting of cryoablation (figures 4 and 5) but also is applicable in the setting of therapies involving direct STING agonist administration.”
    Quote in the paperSubstantial claim
  • May combine two claims.

    Interpretationown data

    Tumor-intrinsic STING signaling drives both the local response to cryoablation and the generation of an effective systemic antitumor immunity.

    “These results provide strong evidence that tumor-intrinsic STING signaling drives both the local response to cryoablation and the generation of an effective systemic antitumor immunity.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Tumor cells undergoing ICD actively export DNA fragments to initiate an innate immune response.

    “Previous studies have reported that tumor cells undergoing ICD actively export DNA fragments to initiate an innate immune response.83 84”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 83 84

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationown data

    An alternative source of STING signaling exists, or STING signaling does not completely account for the therapeutic efficacy of cryoablation.

    “This finding suggests either an alternative source of STING signaling, or that STING signaling does not completely account for the therapeutic efficacy of cryoablation.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    STING deficiency has a reported protective role in tumor cell death.

    “the reported protective role of STING deficiency in tumor cell death.68 69”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 68 69

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The presence of cytosolic dsDNA in APCs triggers host STING-mediated type I IFN activation and adaptive immunity.

    “Consequently, the presence of cytosolic dsDNA in APCs triggers host STING-mediated type I IFN activation and adaptive immunity.17 32 35 36”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 17 32 35 36

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Tumors induced to undergo ICD can serve as 'in situ tumor vaccines' to activate DC and T cells, leading to the generation of an immunogenic hot TME and a robust systemic antitumor immune response.

    “Tumors induced to undergo ICD can serve as ‘in situ tumor vaccines’ to activate DC and T cells, leading to the generation of an immunogenic hot TME and a robust systemic antitumor immune response.13 14”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites 13 14

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationown data

    This suggests a correlation between the lack of tumor cell-intrinsic STING and tumor metastatic tendency or resistance to antitumor immunity.

    “suggesting a correlation between the lack of tumor cell-intrinsic STING and tumor metastatic tendency or resistance to antitumor immunity.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The myeloid STING pathway is required for the antitumor immunity effects associated with multiple cancer therapeutics.

    “reaffirmed prior studies showing the requirement of the myeloid STING pathway for the antitumor immunity effects associated with multiple cancer therapeutics,17 35 36”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 17 35 36

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationown data

    The loss of cryoablation efficacy in STING-/- tumors is not due to intrinsic survival advantage of the STING-/- tumor following cryoablation; rather, it is the lack of antitumor immunity in these tumors following the intervention that resulted in the lack of therapeutic efficacy.

    “These data led us to believe that the loss of cryoablation efficacy in STING-/- tumors is not due to intrinsic survival advantage of the STING-/- tumor following cryoablation; rather, it is the lack of antitumor immunity in these tumors following the intervention that resulted in the lack of therapeutic efficacy.”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Mice harboring the functionally deficient STINGS365A/365A point mutant are still capable of exhibiting STING-related IFN-independent activities.

    “as mice harboring the functionally deficient STINGS365A/365A point mutant are still capable of exhibiting STING-related IFN-independent activities.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 18 20 21

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Recent evidence suggests the existence of IFN-independent activities of STING in hematopoietic-derived cells including T cells.

    “recent evidence suggests the existence of IFN-independent activities of STING in hematopoietic-derived cells including T cells,18 20 21”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 18 20 21

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationreasoning

    Partial and sublethal cryoablation rather than complete cryoablation results in more robust response because leaving live, bulky tumor after the procedure to respond to cryoablated tumors may provide a more robust STING signaling in tumors with a functional STING signaling pathway.

    “These data lend an explanation to the anecdotal clinical observation that partial and sublethal cryoablation rather than complete cryoablation results in more robust response since leaving live, bulky tumor after the procedure to respond to cryoablated tumors may provide a more robust STING signaling in tumors with a functional STING signaling pathway.”
    Quote in the paperSubstantial claim
47 of 47
  • The paper relies on this without support.

    The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood.

    “The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood.”
  • The paper relies on this without support.

    RMS 76-9 originated from male mice, and female mice spontaneously reject inoculated tumor growth at a high frequency.

    “As rhabdomyosarcoma (RMS) cell line RMS 76-9 originated from male mice, female mice spontaneously reject inoculated tumor growth at a high frequency.”
  • The paper relies on this without support.

    STING-/- mice lack functional host STING signaling.

    “mice bearing RMS 76-9STING-/- tumors completely lack STING in both host and tumor.”
  • The authors state this as an assumption.

    In STING-/- mice bearing RMS 76-9STINGwt tumors, the only source of intact STING signaling is the tumor cells.

    “In this model, the only source of intact STING signaling pathway comes solely from RMS 76-9STINGwt, while mice bearing RMS 76-9STING-/- tumors completely lack STING in both host and tumor.”
  • The paper relies on this without support.

    The molecular determinants driving clinical outcomes of tumor cryoablation are not well understood.

    “The molecular determinants driving these clinical outcomes are not well understood.”
  • The paper relies on this without support.

    Cryoablation has a distinct theoretical advantage over high-temperature or radio-ablation techniques in its ability to preserve intact tumor antigens and provide ICD-related DAMPs.

    “A distinct theoretical advantage of cryoablation over high-temperature or radio-ablation techniques is its ability to preserve intact tumor antigens and provide ICD-related DAMPs.”
6 of 6

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Flow-cytometry tumor harvest is reported as both three and seven days after cryoablation

    Minor

    The tumor-isolation Methods assign flow-cytometry harvests to seven days after cryoablation, but the Figure 2 legend reports flow cytometry on tumors harvested three days afterward.

  • T-cell depletion is dated differently in the Methods and Figure 1

    Minor

    The Methods say anti-CD4 or anti-CD8 was administered one day before cryoablation, on day 9 after inoculation. The Figure 1 legend instead says the antibodies were administered on day 10, the day of cryoablation.

2 of 2

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Alshebremi, M., Tomchuck, S. L., Myers, J. T., Kingsley, D. T., Eid, S., Abiff, M., Bonner, M., Saab, S. T., Choi, S. H., & Huang, A. Y.-C.
Affiliations
  • Qassim University (SA)
  • Case Western Reserve University (US)
  • University Hospitals Cleveland Medical Center (US)
  • Rainbow Babies & Children's Hospital (US)
Corresponding author
Huang, Alex Yee-Chen
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2023-08
Volume
11
Issue
8
Pages
e006608
ISSN
2051-1426 (ISSN-L)
OpenAlex
W4385666785
Cited by
14
References
98
Citations by year
2026: 6 · 2025: 7 · 2023: 1
FWCI
1.44
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Alan & Karen Krause Family Foundation (N/A)
  • Sarcoma Foundation of America (836338)
  • Pediatric Cancer Research Foundation (580546)
  • Center for Pediatric Immunotherapy at the Angie Fowler AYA Cancer Institute / UH Rainbow Babies & Children’s Hospital (N/A)
  • The Cleveland Foundation (N/A)
  • St. Baldrick's Foundation (712502, 605146, 550928)
  • ORIP (S10OD024981)
  • Theresia G. & Stuart F. Kline Family Foundation (N/A)
  • Harrington Discovery Institute (N/A)
  • NIH/NCI (F31CA254259, T32CA059366)
  • NIH/NIGMS (T32GM007250)
  • The Char & Chuck Fowler Family Foundation
  • The I'm Not Done Yet Foundation
  • Children’s Cancer Research Fund (897798)
  • Alex's Lemonade Stand Foundation for Childhood Cancer (N/A)
  • Case Comprehensive Cancer Center AYA Oncology Pilot Grant (N/A)
  • Case Comprehensive Cancer Center - VeloSano Bike to Cure Pilot Award
  • The Risman Family Philanthropic Funds
  • MIB Agents
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
STING signaling, cryoablation, abscopal effect, antitumor immunity, tumor microenvironment, lung metastasis, tumor-infiltrating immune cells, treatment response biomarkers
MeSH terms
Animals, Cryosurgery, Lung Neoplasms, Mice, Inbred C57BL, Cytokines, Mice, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-19.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-19.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review